在实验室中对新型NOP受体部分激动剂sunobinopop进行药理学评估
Riccardo Camilotto1, Davide Malfacini1, Pietro Pola2
1Department of Pharmaceutical and Pharmacological Sciences, Section of Pharmacology, University of Padova, Padova, Italy.
Biochemical pharmacology
|May 11, 2025
概括
针对nociceptin/orphanin FQ (N/OFQ) (NOP) 受体的药物Sunobinop在关键测定中显示出部分激素活性. 这项研究为治疗睡眠障碍的作用机制提供了关键的见解.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 药物发现 药物发现 药物发现
背景情况:
- 与睡眠相关的障碍影响全球大量人口.
- 诺西素/孤儿素FQ (N/OFQ) (NOP) 受体是新型睡眠障碍治疗的关键标.
- 苏诺比诺普是一种选择性NOP受体局部激动剂,正在临床试验中.
研究的目的:
- 为了对sunobinop进行全面的药理学表征.
- 阐明sunobinop在NOP受体上的作用方式.
- 提供与治疗睡眠障碍的sunobinop临床评估相关的见解.
主要方法:
- 在体外测试包括调动,G蛋白相互作用,无标签生物阻抗和cAMP抑制.
- 外体检测如NOP-β-Arrestin 2招募和小鼠Vas Deferens刺激等.
- 使用广泛的方法来进行详细的药理分析.
主要成果:
- 苏诺比诺普在测量NOP受体信号传递的多个测试中表现出部分激素活性.
- 在NOP-β-Arrestin 2招募和ex vivo小鼠Vas Deferens试验中观察到竞争对抗性.
- 这些发现证实并扩大了对sunobinop药理学概况的理解.
结论:
- 苏诺比诺普作为NOP受体的部分激动剂,具有上下文依赖的活性.
- 这项研究提供了关于sunobinop的作用机制的宝贵数据.
- 描述支持sunobinop作为药理学工具的实用性及其对睡眠障碍的临床发展.
更多相关视频
相关概念视频
Drug-Receptor Interaction: Agonist
2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K
Opioid Receptors: Overview
330
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
330
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
137
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
137
Drug-Receptor Interaction: Antagonist
2.6K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
2.6K
Drug-Receptor Interactions
4.7K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
4.7K


